AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor

• Komala Ingle,

  Roles Formal analysis, Investigation, Validation, Visualization, Writing – original draft, Writing – review & editing

  Affiliation Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America

  ⨯
• Joseph F. LaComb,

  Roles Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing

  Affiliation Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America

  ⨯
• Lee M. Graves,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Pharmacology, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  ⨯
• Antonio T. Baines,

  Roles Conceptualization, Resources, Writing – original draft, Writing – review & editing

  Affiliations Department of Pharmacology, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Department of Biological & Biomedical Sciences, College of Health & Sciences, North Carolina Central University, Durham, North Carolina, United States of America

  ⨯
• Agnieszka B. Bialkowska

  Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Supervision, Validation, Writing – original draft, Writing – review & editing

  * E-mail: Agnieszka.Bialkowska@stonybrookmedicine.edu

  Affiliation Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America

  https://orcid.org/0000-0003-2127-7714

  ⨯